Inviragen and SingVax have merged their complementary vaccine pipelines and their international product development capabilities to create a company that would develop vaccines for infectious diseases prevalent in emerging economies.
Reportedly, the combined company raised $15m in a Series A equity investment from a syndicate of international venture capital investors, including Charter Life Sciences of Palo Alto, California, Venture Investors of Madison, Wisconsin, BioOne Capital of Singapore and Phillip Private Equity of Singapore.
Dan Stinchcomb, CEO of Inviragen, said: “Post-merger, Inviragen has three vaccines poised to begin human clinical trials. During the next 18 months, these clinical studies will test vaccine safety and measure the immune responses induced by these three vaccines to establish ‘proof-of-concept’ of their efficacy.” These vaccines are designed to protect against Dengue fever, Hand, Foot and Mouth Disease and Japanese Encephalitis, respectively.